Gastroparesis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Gastroparesis (GP) is a syndrome where gastric emptying is delayed without any mechanical obstruction in the gastric outlet. Common symptoms include postprandial fullness (early satiety), nausea, vomiting, and abdominal pain. Nausea is observed in over 90% of patients, while vomiting affects 68% to 84%. Around half of the patients experience feelings of fullness or early satiety even after consuming a small amount of food. Vomiting typically consists of poorly digested food from 1 to 12 hours ago, often accompanied by acid reflux, nausea, abdominal bloating, abdominal pain, changes in blood sugar levels, appetite loss, weight loss, and malnutrition. Bloating and abdominal pain are primarily attributed to sensory changes, while nausea, vomiting, early satiety, and postprandial fullness stem from issues with smooth muscle function and neural denervation, resulting in delayed gastric emptying. It's important to note that psychological disorders do not cause gastric retention in these patients, although psychological distress can exacerbate a patient's perception of symptom severity.

·       The prevalence of cases of Gastroparesis in the USA is 268 to 339 cases per 100,000 population. It was more than twice as common in females than males, with patients aged 58 to 64 years having the highest prevalence and those aged 18 to 27 years having the lowest.

 

Thelansis’s “Gastroparesis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Gastroparesis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Gastroparesis across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Gastroparesis Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Gastroparesis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Gastroparesis, Gastroparesis market outlook, Gastroparesis competitive landscape, Gastroparesis market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)